These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27915425)

  • 1. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Gong Z; Zheng L; Tang Z; Chen Z; Wang W; Bai S; Tang G; Medeiros LJ; Hu S
    Ann Hematol; 2017 Mar; 96(3):501-504. PubMed ID: 27915425
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
    Jiménez-Velasco A; Barrios M; Alcalá M; Heiniger AI
    J Clin Oncol; 2010 Jun; 28(18):e310; author reply e311. PubMed ID: 20479423
    [No Abstract]   [Full Text] [Related]  

  • 4. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
    Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
    Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.
    Bruennert D; Czibere A; Bruns I; Kronenwett R; Gattermann N; Haas R; Neumann F
    Leukemia; 2009 May; 23(5):983-5. PubMed ID: 19052557
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
    Wang W; Chen Z; Hu Z; Yin CC; Li S; Bai S; Bueso-Ramos CE; Medeiros LJ; Hu S
    Blood Cancer J; 2016 Nov; 6(11):e490. PubMed ID: 27813536
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
    Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Wang W; Cortes JE; Liu E; Miranda RN; Zhao C; Yuan J; Lu X; Yang W; Ameri MD; Kantarjian HM; Medeiros LJ; Hu S
    Blood Cancer J; 2016 May; 6(5):e418. PubMed ID: 27152845
    [No Abstract]   [Full Text] [Related]  

  • 9. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW; Druker BJ
    J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The second generation of BCR-ABL tyrosine kinase inhibitors.
    Tauchi T; Ohyashiki K
    Int J Hematol; 2006 May; 83(4):294-300. PubMed ID: 16757427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
    Kelani R; Monem F
    Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J
    Lab Hematol; 2004; 10(3):181-4. PubMed ID: 15529444
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
    Jabbour E; Cortés JE; Kantarjian H
    Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S75-81. PubMed ID: 19254884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 18. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
    Imataki O
    Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
    [No Abstract]   [Full Text] [Related]  

  • 19. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.
    Haferlach C; Bacher U; Schnittger S; Weiss T; Kern W; Haferlach T
    Leukemia; 2010 Mar; 24(3):638-40. PubMed ID: 19865111
    [No Abstract]   [Full Text] [Related]  

  • 20. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
    Takahashi N
    Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.